Swiss medtech CHD secures funding for remote pregnancy monitoring

Swiss medtech startup Connected Health Development (CHD) has raised funding from Venture Kick to advance its remote maternal and fetal monitoring platform. The capital will reportedly support the development of a system combining wearable sensors and digital tools, aiming to enable healthcare providers to monitor pregnancies outside traditional clinical settings.

According to reports, the technology involves a smart textile belt designed to collect data such as ECG readings, uterine activity, and fetal movements. Patients may access basic health indicators via a smartphone app, while clinicians could review more detailed data through a secure portal. The solution is positioned to address challenges like frequent hospital visits for high-risk pregnancies, which some estimates suggest account for a significant portion of annual births globally.

CHD’s leadership has described the funding as part of a broader seed round, with additional commitments reportedly in progress. The company aims to finalize the round in the coming weeks and use the funds to prepare its technology for commercial launch. While some coverage has mentioned sales targets, CHD has not publicly disclosed pricing or revenue projections.

The investment arrives amid growing interest in remote monitoring solutions for maternal health, where staffing constraints and hospital capacity issues have increased demand for scalable alternatives. CHD’s approach—combining hardware with data analytics—aligns with broader trends in healthtech, where startups often pair devices with predictive insights to appeal to healthcare providers. Unlike some femtech products marketed directly to consumers, CHD’s platform appears designed for clinical use, though its ultimate adoption will depend on factors like regulatory approvals and integration with existing systems.

CHD’s ability to attract additional backing suggests investor confidence, but the startup will likely need to demonstrate clinical efficacy to secure larger rounds.

The market for remote pregnancy monitoring remains early but potentially impactful. High-risk pregnancies often require frequent in-person care, creating logistical and financial burdens for patients and providers alike. Solutions like CHD’s could theoretically reduce unnecessary hospital visits while enabling earlier detection of complications, though their success will hinge on navigating regulatory pathways, reimbursement models, and healthcare provider adoption.

CHD’s progress will be worth monitoring as it moves toward commercialization. If the company can secure further funding and validate its technology, it may emerge as a player in a space where few startups have achieved significant scale. For now, the funding represents a step toward addressing a persistent gap in maternal healthcare, though its long-term impact remains to be seen.

Sources: tech.eu